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transforming sequence (ETS) family of 
transcription factors were identified in most 
of PSA-screened prostate cancers. In this 
review, we summarize the identification, 




:ETS gene fusions and their role in 
prostate cancer development. We also 





partners that define distinct classes of ETS 
gene fusions based on the prostate 





 partner. Additionally, we also 
summarize conflicting reports about 
associations between gene fusion status and 
patient outcome. The specificity of ETS gene 
fusions in prostate cancer suggests that they 
may have causal roles in prostate cancer and 





prostate cancer, gene fusion, biomarker 
Chromosomal rearrangements play a causal 
role in haematological and mesenchymal 
malignancies. Importantly, the resulting 
gene fusions can serve as specific 
therapeutic targets, as exemplified by the 
development of imatinib (Gleevec), which 




 gene fusion 
product that defines chronic myeloid 
leukaemia. Recently, gene fusions involving 
the prostate-specific gene transmembrane 




) and members 




Alterations of gene expression and 
subsequent function, whether through 
activation of oncogenes or suppression 
of tumour suppressors, are hallmark 
contributors to the development of 
malignancy. These alterations often result 
from chromosomal translocations or 
deletions of segments of the genome that 
result in modified gene expression or fusion 
of two distinct gene transcripts. Such 
chromosomal structural rearrangements are 
common in haematological malignancies and 
often function as exclusive trigger points 
in oncogenesis [1–3]. For example, the 




 gene from 




 gene of 
chromosome 9, yielding the ‘Philadelphia 




 fusion protein with a constitutively 
active tyrosine kinase domain that drives the 
development of chronic myeloid leukaemia. 
While this is an example of a chromosomal 
translocation resulting in fusion of two 
transcripts resulting in a fusion protein, 
structural rearrangements of the 
chromosome can drive the development of 
malignancy through many methods. These 
alterations can change gene products directly 
or inappropriately modify gene expression by 
associating upstream promoters or regions of 
epigenetic control (e.g. hypermethylation of 
upstream promoters) with other genes 
(Fig. 1).
 
WHY DO FUSIONS MATTER?
 
The pervasive nature of structural 
rearrangements in haematological 
malignancies enables cytogenetics and fusion 
status to determine tumour subtyping and 
appropriate therapy decisions [4]. The modern 
era of targeted drug therapy was bolstered by 
the success of imitanib (Gleevec) development 





 fusion [5]. Unfortunately, 
structural rearrangements are historically 
rare in carcinomas. Besides the obvious 
explanation that the rearrangements may not 
exist, the assumption was that chromosomal 
changes are difficult to discover and 
document in epithelial-based tumours. 
Carcinoma cells are difficult to culture and 
studies based on solid tumour samples detect 
many nonspecific chromosomal changes. 
However, recent advances in genomic 
profiling, through the use of microarrays, 
spectral karyotyping (SKY), and competitive 
genomic hybridization (CGH), has coupled 
with the emerging field of bioinformatics to 
uncover many findings not evident with 
standard analysis techniques. As an example 
of the power of bioinformatic analysis to 
detect new associations from previously 
analysed data, the Chinnaiyan research group 
developed the Cancer Outlier Profile Analysis 
(COPA) algorithm to analyse DNA microarray 
studies, which led to the identification of 





COPA is based on the three theories: 
(i) chromosomal rearrangements and 
amplifications may result in marked 
overexpression of involved genes, (ii) such 
alterations are often heterogeneous in a 
given cancer type, and (iii) the altered gene 
expression in a subset of samples may 
be overshadowed when analysing DNA 
microarray studies using standard analytical 





Thus, COPA is designed to detect genes that 
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have very high expression in only a subset 
of cancer cases, e.g. gene A is highly 
overexpressed in only 5% of tumour samples. 
While the full statistical methodology is 
outside the realm of this review, for every 
gene in a given microarray study, the median 
expression for all samples is centred to 0 and 
the median absolute deviation is set to 1. This 
process compresses a biomarker gene profile 
that has generalized overexpression in cancer 
compared with normal and accentuates 
an outlier gene profile that only has 
overexpression in a subset of cancer cases. As 
is typical for microarray analysis, the genes 
are then rank ordered by the extent of their 
‘outlier’ score to enable selection of genes for 
further characterization and study. Applying 
this method to multiple cancer datasets ranks 
genes with known rearrangements at or near 




 ranks number one 
for outliers from a microarray dataset of 




 gene [7] (Table 1) [6–17]. The results of 
COPA analysis of prostate cancer studies 
identified erythroblastosis virus E26 










 as outliers in a fraction of 
cases with COPA scores in the top 10 for six 








 (21q22.3) are genes 
from the ETS family of transcription factors 
and have previously been implicated in 
oncogenic translocations in Ewing’s sarcoma 
and myeloid leukaemia [18,19]. Furthermore, 
ETS members are functionally redundant in 
cancer development, as only one ETS gene is 
involved in a translocation in each case of 
Ewing’s sarcoma [19]. As further support for 









 was mutually 
exclusive and raised the possibility that the 
overexpression of these genes acts as a 
trigger point in cancer development.
 
DISCOVERY OF PROSTATE GENE FUSIONS
 
To determine if structural rearrangements 








, the RNA from prostate cancer 
samples was characterized quantitatively 
using a PCR–based test. Real-time 
quantitative PCR (qPCR) determines the 
amount of RNA transcript for a gene of 
interest by amplifying a segment of the gene 
transcript and directly measuring the amount 
of transcript during the amplification process 
using fluorescent dyes. When applied to 
prostate cancer, qPCR consistently showed a 












 for cases 





Next, RNA ligase mediated rapid amplification 














transcripts in such samples. Sequencing 


















untranslated region of the prostate specific 





; 21q22.2) (Fig. 2). After 













 in cases with overexpression, qPCR 













 was performed 
to confirm the fusion in a separate group of 
clinically localized prostate cancer samples. 








 was mutually exclusive and fusion 
transcripts could be detected in 95% of cases 








, but not in 













The detection and validation of chromosomal 
alterations producing gene fusions are 
typically based on two technologies: the use 
of PCR-based assays to detect and quantify 
gene expression and fusion transcripts, and 





(FISH) based assays to visualize the 
chromosomal alteration at the genomic level. 
Similar to designing primers to amplify the 
gene transcript, FISH probes are selected from 
genomic DNA sequences that span or abut the 
segment of genomic DNA potentially involved 




Gene alterations by chromosomal 























, Examples of gene 
fusion methods that may drive oncogenesis. Fusion 
of the coding region of genes A and B can result in a 
fusion transcript and associated fusion protein with 
altered function. Alternatively, fusion of Gene A 
upstream promoter regions to the coding region of 
Gene B may alter Gene B expression through trans 
























COPA analysis identifies outliers in cancer samples
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locus were labelled with distinct fluorescent 









showed a pair of separate signals reflecting 
the normal 7 and 22 chromosomes, and a 








 genomic loci. On the other 








 can occur 
through either translocation between both 









 as they 
are located close together on the same 
chromosome arm. Importantly, both 
translocations and chromosomal deletions 
can be detected by specifically designed FISH 
probes. Although qPCR-based detection may 
be ideal for quantifying and characterizing 
the fusion transcript, FISH-based detection 
allows screening of large collection of 
prostate cancer samples through the use of 
tissue microarrays, where cores from tens to 
hundreds of prostate cancers are arrayed in a 
single paraffin block for sectioning. As part of 
the initial description of the ETS fusions, 23 of 
29 cases (79%) of prostate cancer samples 


















 fusions (16 cases) 
[6].
Since the initial description of ETS-family-
member gene fusions in prostate cancer, the 
results have been confirmed through many 
independent centres internationally (Table 2) 
[20–34]. As more cases are screened and 
identified, the exact proportion of cases with 





500 samples studied, multiple 
groups have confirmed the largest proportion 






















(1–10%) [20–22]. As characterization 
continues additional ETS genes have been 



























been identified in ETS fusions (Fig. 2) [23,35].
 
FUSION FUNCTION AS ONCOGENES?
 
While fusions have thus far been described in 
most prostate cancers, the influence of fusion 
status on the development of cancer remains 





genes itself is prostate tissue specific and is 
expressed in both normal and cancerous 





 is induced by 
androgen stimulation in androgen-sensitive 
prostate cancer cell lines [36,37]. Thus, we 









, which contains the elements 
needed to drive prostate tissue expression, 
functions to drive ETS gene overexpression in 
TMPRSS2:ETS-positive prostate cancers. In 
support of this hypothesis, the expression 
of ERG and TMPRSS2:ERG was up-regulated 
by synthetic androgen and blocked with 
bicalutamide (CasodexTM) in VCaP cells, which 
express TMPRSS2:ERG fusion, but not in 
LnCaP cells, which harbour an ETV1 
rearrangement [6,38].
The histological development of prostate 
cancer is often described through a transition 
from benign epithelium to prostatic 
intraepithelial neoplasia (PIN) to frank 
adenocarcinoma and ultimately metastatic 
disease. Based on several observations, it 
FIG. 2. Gene fusions identified in prostate cancer. 
Gene fusions described to date in prostate cancer 
are depicted as gene pairs. Exons are represented by 
numbered boxes and translated and untranslated 
flanking regions are shown with contrasting 
colours. The relative response to synthetic 
androgens R1881 are depicted in relative expression 
units to the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
Androgen Response
1 2 3 14
TMPRSS2
4–13 1 2 3 4 5–11 12
ETV1
1 4 5–11 12 TMPRSS2:ETV1
1 2 3 14
TMPRSS2
4–13 1 2 3 4 5–10 11
ERG
1 4 5–10 11 TMPRSS2:ERG





0 3–7 8–12 13 TMPRSS2:ETV4
0
1 2 3 4 5–11 12
ETV1SLC45A3
1 2 3 54
1 5–11 12 SLC45A3:ETV1
1 2 3 4 5–11 12
ETV1HERV–K_22q11.23
1 2
1 2 5–11 12 HERV–K 22q11.23:ETV1
1 2 3 4 5–11 12
ETV1C15orf21
1 2 3 654
1 2 6 7–11 12 C15orf21:ETV1
1 2 3 4 5–11 12
ETV1HNRPA2B1
1 2 3–9 1110























































































TABLE 2 Frequency of ETS outlier expression and TMPRSS2:ETS expression. The number and frequency of 









Cerveira et al. [26] 34 17 (50) 0
Demichelis et al. [25] 111 17 (15.3) ND
Hermans et al. [27] 11 5 1
Iljin et al. [28] 19 7 (36.8) ND
Lapointe et al. [23] 63 44 (69.8) ND
Mehra et al. [20] 65/53 36 (55.4) 1 (1.9)
Mosquera et al. [21] 253 120 (47.4) ND
Nam et al. [29] 26 11 (42.3) ND
Perner et al. [30] 24 12 (50) 0
135 65 (48.1) ND
Rajput et al. [31] 86 35 (40.7) ND
Soller et al. [32] 18 14 (77.8) 0
Tu et al. [33] 82 35 (43) 1 (1.2)
Wang et al. [24] 59 35 (59.3) ND
Winnes et al. [22] 50 18 (36) 0
Yoshimoto et al. [34] 15 6 0
Total+: 477/1051 (45.4) 3/287 (1)
*Assessing TMPRSS2:ETS rearrangements (by FISH or qPCR) are indicated by the last name of the first 
author; ND, no assessment of TMPRSS2:ETV1 status was made.
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appears likely that ETS gene fusions may be a 
genetic trigger for the PIN to adenocarcinoma 
transition through the development of 
invasion. For example, in a FISH-based study 
of >400 tissue samples, Perner et al. [39] 
identified the presence of the TMPRSS2:ERG 
fusion in 48.5% of clinically localized prostate 
cancers, 30% of hormone-naive metastases, 
33% of hormone-refractory metastases, and 
in 19% of high-grade PIN lesions that were 
always found intermingling with cancer foci. 
However, no benign prostate, BPH or 
proliferative inflammatory atrophy (PIA) 
tissue samples harboured TMPRSS2:ERG 
fusions. Furthermore, in an integrative 
molecular profiling of prostate cancer 
progression, we found that PIN and prostate 
cancer had a very similar expression profile, 
suggesting a limited number of genetic 
changes needed to drive the PIN to prostate 
cancer transition. Additionally, the ectopic 
overexpression of the ETV1 fusion product in 
the immortalized benign prostatic epithelial 
cell line RWPE, markedly increased cell 
invasion through a modified basement 
membrane without affecting proliferation. 
Finally, generation of transgenic mice 
overexpressing the ETV1 or ERG fusion 
product resulted in the development of 
mouse PIN (mPIN; [40–42]). Synthesizing the 
results of these studies suggests that initial 
genetic lesions, such as single-copy loss of 
the tumour suppressors PTEN or NKX3-1, 
dysregulate cellular proliferation and drive 
the benign to PIN transition, and in such a 
context TMPRSS2:ETS gene fusions trigger the 
development of invasion and carcinoma. The 
RWPE-ETV1 results and the development of 
mPIN but not carcinoma in transgenic mice 
suggest that ETS fusions are probably not 
sufficient for transformation and require pre-
existing genetic lesions. Thus, the generation 
of transgenic mice recapitulating both initial 
lesions and ETS fusions products will probably 
provide a highly relevant model for in vivo 
studies of prostate cancer development.
Initially, TMPRSS2 was the only 5′ partner 
identified in ETS gene fusions in prostate 
cancer. As larger cohorts were characterized, 
while the percentage of TMPRSS2:ERG-
positive cancers closely matched the 
percentage of cancers with ERG outlier 
expression, fewer TMPRSS2:ETV1-positive 
cancers were being identified based on the 
percentage of cases with ETV1 overexpression. 
Thus, we used RLM-RACE to characterize 
additional cancers with ETV1 outlier 
expression. Unexpectedly, we discovered a 
family of 5′ fusion partners involved in ETV1 
gene fusions, including the 5′ untranslated 
regions from SLC45A3, HERV-K_22q11.3, 
C15ORF21 and HNRPA2B1 [40]. As these 5′ 
partners are differentially regulated by 
androgen as described below (androgen-
induced, androgen-repressed and androgen-
insensitive), they define distinct classes of ETS 
gene rearrangements. Thus, as a prospective 
method of classifying ETS member fusions, 
our laboratory has suggested a classification 
schema based on the 5′ partner for ETS 
members (Fig. 3).
Fusions involving the prostate-specific 
androgen-induced gene TMPRSS2 to ETS 
genes comprise the most frequent class of 
rearrangements (Class I). ETS fusions with 
other prostate-specific androgen-induced 
genes (e.g. SLC45A3) and endogenous 
retroviral elements (e.g. HERV-K_22q11.3) 
define Class IIa and Class IIb rearrangements, 
respectively. Class III rearrangements 
represent 5′ prostate-specific androgen-
repressed partners, like C15ORF21. A strong 
5′ ubiquitous promoter drives aberrant ETS 
expression in Class IV rearrangements. 
Characterizing prostate cancer cell lines with 
ETV1 rearrangements, we found that through 
distinct mechanisms, the entire ETV1 locus is 
rearranged to a 1.5-megabase prostate-
specific region at 14q13.3–14q21.1 in both 
LNCaP cells (cryptic insertion) and MDA-PCa 
2B cells (balanced translocation). Thus, 
rearrangement of the entire ETS gene into 
a prostate-specific-region defines Class V 
rearrangements [40].
ASSOCIATION WITH OUTCOMES
Recently, the influence of fusion status on 
cancer outcome has begun to be addressed. 
Conflicting data supports the association of 
TMPRSS2:ERG fusion with both improved 
and worsened patient outcomes. The 
limitations of small cohort size and varied 
populations are partially responsible for 
these findings, and have led to the lack of 
consensus about whether gene fusions 
influence the risk of prostate cancer 
progression or recurrence. Initial screening 
studies seeking to determine the proportion 
of cases with gene fusion found no 
association with PSA recurrence [20,23]. 
Many of these studies were unable to 
determine the association with PSA 
recurrence due to limitations in follow-up 
and instead reported the association with 
assumed surrogates of cancer risk such as 
disease stage and Gleason grade. While some 
studies have shown correlation with higher 
stage disease [20], others report either no 
association with Gleason score [23,39] or an 
association with lower Gleason score and 
better survival [22]. On the other hand, a 
surgical series of 59 patients including 34 
cases with PSA recurrence and advanced 
pathological stage, recently reported an 
association between certain isoforms of 
fusion with early recurrence and seminal 
vesicle invasion [24]. The number of exons 
from TMPRSS2 and the alignment of 
FIG. 3. Classes of chromosomal rearrangements potentially activating ETS oncogenes in prostate cancer. Five 
general classes of chromosomal rearrangements activate ETS family members in the development of 
prostate cancer. Classes are determined by the prostate-specificity and androgen-responsiveness of the 5′ 
fusion partner for the ETS family member. The presence of detectable fusion transcripts the type of genomic 
sequence of the 5′ partner are noted. Examples of each class are indicated with graphic representation of 
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TMPRSS2 with downstream ERG exons 
determined up to eight isoforms, including 
the two initially described by Tomlins et al. [6] 
and had a significant impact on disease 
characteristics. In a separate surgical series 
of 26 patients including 11 (42%) with 
TMPRSS2:ERG fusion, patients with fusion 
had a higher rate of biochemical recurrence 
(80%) than did fusion negative patients 
(38%) [29]. Additionally, TMPRSS2:ERG fusion 
was significantly associated with a higher 
likelihood of prostate cancer-specific death in 
a cohort of 111 men in a watchful-waiting 
cohort [25]. Although TMPRSS2:ERG fusion 
may be associated with lower disease survival 
in a European watchful-waiting cohort, the 
patient population from this cohort differs 
from the patient cohorts identified through 
PSA-screening in the USA [20]. The overall 
proportion of cases with gene fusion is much 
lower, only 15%, than the proportion noted 
in screening populations in the USA of >50%, 
and therefore caution should be used before 
extrapolating the study conclusions to 
a population with a different fusion 
penetrance. Furthermore, these trials reflect 
small cohorts when compared with the 
thousands of patients presenting for prostate 
cancer treatment and results should be 
confirmed on larger, more inclusive cohorts 
before fusion status can be utilized to risk 
stratify patients with prostate cancer.
FUTURE APPLICATIONS
Gene fusion status may eventually be used for 
pretreatment risk stratification, for enrolment 
in active surveillance trials, or for guidance 
during surveillance after therapy. Given 
the protracted course of prostate cancer 
progression, supporting data from 
prospective trials may take years to 
accumulate. However, due to the specificity of 
gene fusions for prostate cancer compared 
with normal, PIA, or BPH nodules, fusion 
status is currently being developed as a 
biomarker for prostate cancer presence [39]. 
The detection of fusion transcripts in urine 
samples of men with prostate cancer ‘opened 
the door’ for trials incorporating prostate 
cancer fusions in genetic screening tests for 
prostate cancer [43]. We recently completed a 
prospective trial designed to predict cancer 
detection on biopsy by analysing novel 
urinary markers for prostate cancer, including 
gene fusion. Urinary expression of seven 
potential markers, including TMPRSS2:ERG 
fusion, was measured in 236 men presenting 
for prostate biopsy or prostatectomy. We 
generated receiver operator characteristic 
curves for individual markers and for a 
multiplexed combination of markers. 
Incorporating gene fusion status with other 
urinary prostate cancer markers improved on 
the testing characteristics of any single 
marker test, including serum PSA [44]. In a 
similar analysis, Hessels et al. [45] combined 
fusion status with urinary PCA3 to improve 
the ability to predict cancer presence in 108 
men presenting for biopsy. With most cancers 
containing gene fusions of one form or 
another, a test designed to identify fusions 
may improve prostate cancer detection before 
biopsy by combining tests for each fusion 
subtype.
In addition to improved detection, fusion 
partners potentially determine tumour 
biology through androgen regulation and 
may predict response to hormonal 
treatments. As proposed in the fusion 
classification schema, sensitivity to androgen 
stimulation separates fusion pairs with the 
potential to increase transcription factor 
signalling through androgen-sensitive 
promoters or androgen-response elements. 
Conversely, androgen-repressed fusion 
partners, such as C15ORF21, may further 
stimulate cancer progression in the 
androgen-ablation state common with 
hormonal manipulations. Furthermore, if 
studies confirm the association of gene 
fusions with prostate cancer outcomes, the 
preoperative determination of fusion status 
would improve patient counselling before 
therapy.
CONCLUSIONS
The detection and confirmation of gene 
fusions in prostate cancer may eventually 
rival the discovery of PSA as a prostate cancer 
biomarker. Fusion proteins and alterations in 
gene expression because of fusions may act as 
trigger points in malignant transformation 
and progression. While the detection of 
gene fusions has already changed the 
classification, detection, and treatment 
pathways for haematological cancers, the 
application of gene fusions in prostate cancer 
is currently in its infancy. Basic science and 
xenograft experiments have explored the 
ability of these fusions to influence prostate 
pathology in cancer development. While early 
clinical research utilizing surgical cohorts 
have implicated a link between fusion status 
and disease outcome after treatment, future 
studies are needed before utilizing fusion 
status as a prognostic marker of cancer 
outcome. Further applications, including 
improved diagnostics based on urinary fusion 
detection, are currently being explored and 
indicate the potential for prostate cancer 
gene fusions to change the paradigm of 
prostate cancer detection, risk-stratification, 
and treatment.
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